You're right, but there's a time/pain component. So far, its my opinion that BP's influence over the EFF-DA is playing a significant part in the response, or lack thereof, in moving forward at a much faster pace with leronlimab; something they've proven to be able to do with remdesivir and convalescent plasma.

If it goes on long enough, potentially even beyond CV19 (or at least until a better drug than remdesivir comes along even if its not as good as leronlimab), and the FDA continues to slow roll on BLA.....well....maybe not the hard core amongst you CYDY investors, but most would probably be willing to cash out with a large windfall and give up on the massive one.